NAGE · Niagen Bioscience, Inc.
$3.02
-0.03 (-0.98%)
At close · Aug 14
Market Cap
$242.13M
Shares
79.13M
Niagen Bioscience, Inc. Earnings Call Transcripts
Every quarterly earnings call for Niagen Bioscience, Inc. (NAGE) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▼1.4%
$17.06M
−$985,000
'22 Q3
22-11-02
▲18.2%
$21.00M
−$1.42M
'22 Q4
23-03-08
▲30.7%
$22.56M
−$1.90M
'23 Q1
23-05-10
▲21.5%
$20.32M
−$2.19M
'23 Q2
23-08-09
▲14.3%
$19.50M
−$959,000
'23 Q3
23-11-08
▲1%
$21.20M
$114,000
'23 Q4
24-03-06
▼1.8%
$22.15M
−$492,000
'24 Q1
24-05-08
▲11.9%
$22.74M
−$15,000
'24 Q2
24-08-07
▲31.2%
$25.58M
$1.88M
'24 Q3
24-10-31
▲37.4%
$29.12M
$7.18M
'24 Q4
25-03-04
▲37.6%
$30.48M
$5.06M
'25 Q1
25-05-07
▲36.8%
$31.12M
$3.61M
'25 Q2
25-08-06
▲32.9%
$33.99M
$4.58M
'25 Q3
25-11-04
▲16.2%
$33.84M
$4.13M
'25 Q4
26-03-04
▲3.3%
$31.47M
$6.32M
'26 Q1
26-05-06
LATEST
▼4.3%
$29.79M
$963,000
'26 Q2
26-08-04
Conference
Investor event
2026-08-27
Midwest IDEAS Investor Conference
Scheduled
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-08-11
Canaccord Genuity 46th Annual Growth Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-08-04
Niagen Bioscience Second Quarter 2026 Earnings Conference Call
Positive tone
NanoCloud (water-soluble Niagen)
FDA lawsuit / motion to dismiss
Asia Pacific / Watsons partnership
Revenue
$29.79M
▼ 4.3% YoY Diluted EPS
$0.01
▼ 75% YoY Gross margin
64.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-05-06
Niagen Bioscience, Inc. Q1 FY2026 Earnings Call
Confident tone
Revenue and financial performance
Retail distribution strategy
Niagen Plus at-home injection launch
Revenue
$31.47M
▲ 3.3% YoY Diluted EPS
$0.07
▲ 16.7% YoY Gross margin
63.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-03-04
Niagen Bioscience, Inc. Q4 FY2025 Earnings Call
Confident tone
Financial Performance and 2026 Guidance
FDA Litigation and NMN Regulation
Competition and Market Growth
Revenue
$33.84M*
▲ 16.2% YoY Gross margin
64.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-04
Niagen Bioscience, Inc. Q3 FY2025 Earnings Call
Confident tone
Niagen Plus / Clinic & Injection Expansion
FDA Decision on NMN / Competitive Landscape
Revenue Growth & Financial Performance
Revenue
$33.99M
▲ 32.9% YoY Diluted EPS
$0.05
▲ 150% YoY Gross margin
64.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-06
Niagen Bioscience, Inc. Q2 FY2025 Earnings Call
Confident tone
Parkinson's Drug Pathway
Revenue Growth
Niagen Plus / Clinic Channel
Revenue
$31.12M
▲ 36.8% YoY Diluted EPS
$0.04
Gross margin
65.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-07
Niagen Bioscience, Inc. Q1 FY2025 Earnings Call
Confident tone
Niagen Plus (IV and injectables)
E-commerce / Tru Niagen
Pharmaceutical pipeline / clinical trials
Revenue
$30.48M
▲ 37.6% YoY Diluted EPS
$0.06
Gross margin
63.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-04
Niagen Bioscience, Inc. Q4 FY2024 Earnings Call
Confident tone
E-commerce and Tru Niagen channel
Niagen IV and Niagen Plus launch
Niagen ingredient business (food and pharmaceutical grade)
Revenue
$29.12M*
▲ 37.4% YoY Gross margin
62.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-10-31
Niagen Bioscience, Inc. Q3 FY2024 Earnings Call
Confident tone
Niagen IV / Niagen Plus launch in clinics
E-commerce and TRU Niagen direct-to-consumer
Executive transition (new CFO)
Revenue
$25.58M
▲ 31.2% YoY Diluted EPS
$0.02
Gross margin
63.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-07
Niagen Bioscience, Inc. Q2 FY2024 Earnings Call
Revenue
$22.74M
▲ 11.9% YoY Diluted EPS
$0.00
Gross margin
60.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-08
Niagen Bioscience, Inc. Q1 FY2024 Earnings Call
Positive tone
Scientific Research & Pipeline
Retail Distribution Expansion
E-commerce & Digital Channels
Revenue
$22.15M
▼ 1.8% YoY Diluted EPS
$-0.01
Gross margin
60.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-03-06
Niagen Bioscience, Inc. Q4 FY2023 Earnings Call
Positive tone
Gross margin and mix
Q4 financial performance
Partnerships and partner brands
Revenue
$21.20M*
▲ 1% YoY Gross margin
61.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-08
Niagen Bioscience, Inc. Q3 FY2023 Earnings Call
Revenue
$19.50M
▲ 14.3% YoY Diluted EPS
$-0.01
Gross margin
61.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-09
Niagen Bioscience, Inc. Q2 FY2023 Earnings Call
Revenue
$20.32M
▲ 21.5% YoY Diluted EPS
$-0.03
Gross margin
60.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-10
Niagen Bioscience, Inc. Q1 FY2023 Earnings Call
Revenue
$22.56M
▲ 30.7% YoY Diluted EPS
$-0.03
Gross margin
59.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-08
Niagen Bioscience, Inc. Q4 FY2022 Earnings Call
Revenue
$21.00M*
▲ 18.2% YoY Gross margin
57.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-02
Niagen Bioscience, Inc. Q3 FY2022 Earnings Call
Revenue
$17.06M
▼ 1.4% YoY Diluted EPS
$-0.01
Gross margin
59.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-10
Niagen Bioscience, Inc. Q2 FY2022 Earnings Call
Revenue
$16.73M
▼ 5.5% YoY Diluted EPS
$-0.09
Gross margin
60.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-12
Niagen Bioscience, Inc. Q1 FY2022 Earnings Call
Revenue
$17.26M
▲ 17.5% YoY Diluted EPS
$-0.11
Gross margin
61.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-03-09
Niagen Bioscience, Inc. Q4 FY2021 Earnings Call
Revenue
$17.76M*
▲ 15% YoY Gross margin
61.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-03
Niagen Bioscience, Inc. Q3 FY2021 Earnings Call
Revenue
$17.31M
▲ 22.1% YoY Diluted EPS
$-0.13
Gross margin
61.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-03
Niagen Bioscience, Inc. Q2 FY2021 Earnings Call
Revenue
$17.70M
▲ 15.8% YoY Diluted EPS
$-0.08
Gross margin
61.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-06
Niagen Bioscience, Inc. Q1 FY2021 Earnings Call
Revenue
$14.68M
▲ 2.4% YoY Diluted EPS
$-0.12
Gross margin
62.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-03-10
Niagen Bioscience, Inc. Q4 FY2020 Earnings Call
Revenue
$15.45M*
▲ 18% YoY Gross margin
61.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-04
Niagen Bioscience, Inc. Q3 FY2020 Earnings Call
Revenue
$14.18M
▲ 17.6% YoY Diluted EPS
$-0.07
Gross margin
59.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-06
Niagen Bioscience, Inc. Q2 FY2020 Earnings Call
Revenue
$15.29M
▲ 37.7% YoY Diluted EPS
$-0.06
Gross margin
59.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-11
Niagen Bioscience, Inc. Q1 FY2020 Earnings Call
Revenue
$14.35M
▲ 42.8% YoY Gross margin
57.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-03-10
Niagen Bioscience, Inc. Q4 FY2019 Earnings Call
Revenue
$13.09M*
▲ 44.4% YoY Gross margin
57.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–29 of 29 earnings calls
Key facts
CIK
1386570
CUSIP
171077407
13F (30d)
139 filings
137 filers
Visit website
Investor relations